|
gptkbp:instanceOf
|
gptkb:chemical_compound
investigational drug
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:CASNumber
|
329093-07-4
|
|
gptkbp:chemicalClass
|
purines
|
|
gptkbp:clinicalTrialPhase
|
Phase II (as of 2023)
|
|
gptkbp:developedBy
|
gptkb:Cyclacel_Pharmaceuticals
|
|
gptkbp:discoveredBy
|
gptkb:Laurent_Meijer
gptkb:David_Lane
|
|
gptkbp:hasInChIKey
|
QXJYYZQXQZJHKK-IBGZPJMESA-N
|
|
gptkbp:hasMolecularFormula
|
C19H26N6O
|
|
gptkbp:hasSMILES
|
CCN(C[C@@H](O)CN1C=NC2=C1N=CN(C2NCc3ccccc3)C(C)C)C
|
|
gptkbp:hasUNII
|
6Z5B6HVF6O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Seliciclib
|
|
gptkbp:investigatedBy
|
gptkb:cancer
inflammatory diseases
cystic fibrosis
|
|
gptkbp:IUPACName
|
gptkb:2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine
|
|
gptkbp:legalStatus
|
investigational
|
|
gptkbp:mechanismOfAction
|
cyclin-dependent kinase inhibitor
|
|
gptkbp:meltingPoint
|
>200°C
|
|
gptkbp:molecularWeight
|
354.45 g/mol
|
|
gptkbp:PubChem_CID
|
140995
160355
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:synonym
|
gptkb:CYC202
R-roscovitine
|
|
gptkbp:target
|
gptkb:CDK7
gptkb:CDK9
gptkb:CDK2
|
|
gptkbp:bfsParent
|
gptkb:roscovitine
|
|
gptkbp:bfsLayer
|
6
|